# DESCRIPTION

## GOVERNMENT SUPPORT CLAUSE

- acknowledge government support

## BACKGROUND OF THE INVENTION

### Field of the Invention

- define field of invention

### Description of the Related Art

- summarize limitations of BRAF inhibitors

## SUMMARY OF THE INVENTION

- outline methods of reducing resistance

## DETAILED DESCRIPTION OF THE INVENTION

- define terms
- describe embodiments of method for reducing resistance in individual with drug resistant cancer
- describe administration of Hippo signaling pathway inhibitor and BRAF inhibitor
- describe method of reducing resistance in individual with BRAF inhibitor resistant cancer
- describe administration of Hippo signaling pathway inhibitor and BRAF inhibitor in BRAF inhibitor resistant cancer
- describe method of treating BRAF inhibitor resistance in individual having BRAF inhibitor resistant cancer
- describe method of treating individual having malignant melanoma
- provide examples of embodiments

### EXAMPLE 1

- list reagents and antibodies
- describe immunoblotting and immunostaining protocols
- outline cell culture and treatment methods
- detail tumor xenograft and invasion assays

### EXAMPLE 2

- introduce YAP1 and TAZ as BRAF inhibitors resistance factors

### EXAMPLE 3

- study role of YAP1 and TAZ in MCS cells

### EXAMPLE 4

- study role of TEAD transcription factors in MCS cells

### EXAMPLE 5

- study pharmacologic inhibition of YAP1 and BRAF(V600E) on MCS cell survival

### EXAMPLE 6

- study verteporfin suppression of survival of other PLX4032-resistant cell lines

### EXAMPLE 7

- study PLX4032 resistant cell response to ERK inhibitor

### EXAMPLE 8

- study impact of verteporfin and BRAF inhibitors co-treatment on tumor formation

### EXAMPLE 9

- study verteporfin treatment restores tumor response to BRAF inhibitors
- study biochemical status of verteporfin/PLX4032-treated tumors

